Form4insider filings, from the source

SEC Form 4 · accession 0001209191-18-033891

Iterum Therapeutics plc · ITRM

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Jeffrey R. Schaffnit
Officer — Chief Commercial Officer
Period of report
May 24, 2018
Accepted (ET)
May 29, 2018 · 5:08 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001659323

Table I — non-derivative securities

No Table I lines on this filing.

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Stock Option (Right to Buy)F1$13.00May 24, 2018A25,461A—May 23, 2028Ordinary Shares25,46125,461D
Stock Option (Right to Buy)F2$13.00May 24, 2018A6,365A—May 23, 2028Ordinary Shares6,3656,365D

Explanation of responses